New CD22 CAR T-cells for pediatric R/R B-ALL is highly effective

Dr Jing Pan, of Beijing Boren Hospital, Beijing, P.R. China, discusses a new anti-CD22 CAR T-cell immunotherapy for pediatric relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). Dr Pan ex... Author: VJHemOnc Added: 08/15/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts